Fool.com
The World's Greatest Investing Community
Results 1 - 10 of 20 : 1 2 Next
Investors still think highly of these companies, despite their fire-sale prices.
It can pay to catch rising stars.
Pharma's Next Home Run Drug Could Be 4 Singles Instead
With mixed success in the women's health field, drugmakers try to turn a single compound into a treatment for several diseases and conditions.
It can pay to catch rising stars.
It can pay to catch rising stars.
Some investors are warming up to these previously unloved companies.
Some investors are getting behind these stocks that may be set to run.
The FDA Leaves Pfizer in the Waiting Room
The EU loves its new osteoporosis drug, but what about the U.S.?
Glaxo Cuts Jobs, Guidance -- and the Kitchen Sink
With sales dropping, more cuts were inevitable.
While low-priced stocks can be cheap for a reason, they might also present some great, overlooked investment opportunities.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK